Outcomes of Anti-VEGF Therapy in Eyes with Diabetic Macular Edema and Other Retinal Vascular Diseases

AI Generated Summary*

A systematic review collated evidence on anti-VEGF treatment for adults with diabetic macular edema, macular edema from retinal vein occlusion, and neovascular age-related macular degeneration. From 753 identified records, 18 studies spanning randomized trials, prospective cohorts, retrospective analyses and observational work met the criteria. In DME, the share of patients gaining 15 or more ETDRS letters fell between 18.1% and 44.8%, mean acuity changes across included studies ranged from roughly +4 to +21 letters, and central macular thickness reductions of 183.1 to 294 um were noted. Randomized trials showed low bias risk on most domains; retrospective and registry studies rated worse. Comparisons with laser or corticosteroid treatment and long-term safety were outside its scope.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.